Exendin-3 (9-39) amide
(Synonyms: 艾塞那肽,Avexitide;Exendin (9-39)) 目录号 : GC16482
Exendin3(9-39) amide 是一种特异性的 exendin 受体拮抗剂。
Cas No.:133514-43-9
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Exendin3(9-39) amide is a specific exendin receptor antagonist. Exendin-3 increased cellular cAMP levels and amylase release from dispersed acini from guinea pig pancreas.[1]
In vitro experiment it shown that at 0.1-3 nM low concentrations caused a 12-fold increase in CAMP, whereas 0.3-3p~ higher concentrations caused an additional 24-fold increase in CAMP. Exendin-3 can interact with at least two receptors on guinea pig pancreatic acini; at >l00 nM high concentrations the peptide interacts with VIP receptors, so that a large increase in cAMP and stimulating amylase release; at 0.1-3 nM lower concentrations, the peptide interacts with a putative exendin receptor, result in causing a smaller increase in cAMP of undetermined function. And exendin-3(9-39) amide inhibits the actions of exendin-3 with IC 50 of 20 nM.[1] In oxLDL-stimulated Raw264.7 cells, treatment with 1-100 nmol/L excendin-3, it shown that an increased ROS and MDA, but a decreased SOD in a dose-dependent manner.[5] With 1 μM Exendin-3(9–39) pretreatment of the brain slice caused no change in the basal mPSC frequency, as well as no alteration in the basal firing rate was observed.[2]
In vivo experiment it demonstrated that Exendin-3 (9-39) amide (10x7 mol l-1) inhibits GLP-1R but no effect on GLP-2 induced inotropism, lusitropism and coronary motility.[3] In vivo experiment it shown that treatment with 100 nM exendin-3 (9-39) by luminally, the acceleratory effect of GLP-1 was blocked. [4]
References:
[1].Raufman JP, et al. Exendin-3, a novel peptide from Heloderma horridum venom, interacts with vasoactive intestinal peptide receptors and a newly described receptor on dispersed acini from guinea pig pancreas. Description of exendin-3(9-39) amide, a specific exendin receptor antagonist. J Biol Chem. 1991 Feb 15;266(5):2897-902.
[2].Farkas I, et al. Glucagon-Like Peptide-1 Excites Firing and Increases GABAergic Miniature Postsynaptic Currents (mPSCs) in Gonadotropin-Releasing Hormone (GnRH) Neurons of the Male Mice via Activation of Nitric Oxide (NO) and Suppression of Endocannabinoid Signaling Pathways. Front Cell Neurosci. 2016 Sep 12;10:214.
[3].Angelone T, et al. Receptor identification and physiological characterisation of glucagon-like peptide-2 in the rat heart. Nutr Metab Cardiovasc Dis. 2012 Jun;22(6):486-94.
[4].Nakamori H, et al. Mechanisms underlying the prokinetic effects of endogenous glucagon-like peptide-1 in the rat proximal colon. Am J Physiol Gastrointest Liver Physiol. 2021 Dec 1;321(6):G617-G627.
[5].Wang YG, et al. Liraglutide reduces oxidized LDL-induced oxidative stress and fatty degeneration in Raw 264.7 cells involving the AMPK/SREBP1 pathway. J Geriatr Cardiol. 2015 Jul;12(4):410-6.
Exendin3(9-39) amide 是一种特异性的 exendin 受体拮抗剂。 Exendin-3 增加了豚鼠胰腺分散腺泡的细胞 cAMP 水平和淀粉酶释放。[1]
体外实验表明,在 0.1-3 nM 的低浓度下,CAMP 会增加 12 倍,而 0.3-3p~ 较高的浓度会导致 CAMP 增加 24 倍。 Exendin-3可与豚鼠胰腺腺泡上的至少两种受体相互作用；在 >l00 nM 高浓度下,该肽与 VIP 受体相互作用,使 cAMP 大量增加并刺激淀粉酶释放；在 0.1-3 nM 的较低浓度下,该肽与假定的毒蜥外泌肽受体相互作用,导致功能未定的 cAMP 的增加较小。 exendin-3(9-39) amide 抑制 exendin-3 的作用,IC 50 为 20 nM。[1] 在 oxLDL 刺激的 Raw264.7 细胞中,用 1-100 nmol/ L exendin-3, 它显示 ROS 和 MDA 增加,但 SOD 降低,呈剂量依赖性。[5] 用 1 μM Exendin-3(9-39) 预处理大脑切片不会引起基础 mPSC 频率的变化,也不会观察到基础放电率的变化。[2]
体内实验证明 Exendin-3 (9-39) 酰胺 (10x7 mol l-1) 抑制 GLP-1R,但对 GLP-2 诱导的收缩力、向心力和冠状动脉运动没有影响.[3]体内实验表明,100 nM exendin-3 (9-39) luminally 处理后,GLP-1 的加速作用被阻断。 [4]
| Cell experiment [1]: | |
|
Cell lines |
Raw264.7 macrophages |
|
Preparation Method |
The cells were incubated with oxLDL (50 µg/mL), liraglutide (0.1, 0.5, 1 and 2 nmol/L) or exendin-3 (9-39) (1, 10 and 100 nM) alone, or in combination. |
|
Reaction Conditions |
1, 10 and 100 nM, 37°C, 48h |
|
Applications |
Compared with the liraglutide group, oxLDL-stimulated Raw264.7 cells-treated with excendin-3 (1-100 nmol/L) showed an increased ROS and MDA, but a decreased SOD in a dose-dependent manner. |
| Animal experiment [2]: | |
|
Animal models |
Male Wistar rats |
|
Preparation Method |
Group I: sham surgery rats. Rats were not subjected to nerve transection and the left sciatic nerve was gently exposed and muscle and skin are sutured. Group II: PSNT-vehicle group (nerve-transected group infused with saline). Group III: PSNT-TEN group (nerve-transected group infused with teneligliptin). Group IV: PSNT-TEN + EXE group (nerve-transected group infused with teneligliptin + Exendin-3 (9–39) amide). Group IV: PSNT-Mor (nerve-transected group infused with Morphine). The animal behavior test was performed on Day -1 (Pre-surgery), Day 7 (7 days post-surgery), and Day 8, day 10, Day 12, and Day 14. |
|
Dosage form |
0.1 μg/1 μL/h, i.p. |
|
Applications |
Co-infusion of 0.1 µg GLP-1 antagonist EXE did not reverse TEN-induced acute antinociception in PSNT rats. |
|
References: [1]. Wang YG, et al. Liraglutide reduces oxidized LDL-induced oxidative stress and fatty degeneration in Raw 264.7 cells involving the AMPK/SREBP1 pathway. J Geriatr Cardiol. 2015 Jul;12(4):410-6. [2]. Kuthati Y, et al. Teneligliptin Exerts Antinociceptive Effects in Rat Model of Partial Sciatic Nerve Transection Induced Neuropathic Pain. Antioxidants (Basel). 2021 Sep 9;10(9):1438. |
|
| Cas No. | 133514-43-9 | SDF | |
| 别名 | 艾塞那肽,Avexitide;Exendin (9-39) | ||
| Canonical SMILES | CCC(C(/N=C(O)/C(/N=C(O)/C(/N=C(O)/C(/N=C(O)/C(/N=C(O)/C(/N=C(O)/C(/N=C(O)/C(/N=C(O)/C(/N=C(O)/C(/N=C(O)/C(/N=C(O)/C(/N=C(O)/C(/N=C(O)/C(/N=C(O)/C(N)CC(O)=O)CC(C)C)CO)CCCCN)CCC(O)=N)CCSC)CCC(O)=O)CCC(O)=O)CCC(O)=O)C)C(C)C)CCCNC(N)=N)CC(C)C)CC1=CC=CC=C1)/C( | ||
| 分子式 | C149H234N40O47S | 分子量 | 3369.79 |
| 溶解度 | ≥ 168.5mg/mL in DMSO;Water100 mg/mL (29.68 mM);Ethanol100 mg/mL (29.68 mM) | 储存条件 | Desiccate at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 0.2968 mL | 1.4838 mL | 2.9675 mL |
| 5 mM | 0.0594 mL | 0.2968 mL | 0.5935 mL |
| 10 mM | 0.0297 mL | 0.1484 mL | 0.2968 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet